Dupixent for eosinophilic esophagitis (EoE) is currently treated as an ongoing, long-term therapy with no defined stopping point. Because EoE is a chronic condition driven by immune overactivity, the expectation is that you’ll continue injections indefinitely to keep inflammation and symptoms under control. Clinical trials have studied treatment out to 52 weeks, and the improvements patients saw at 24 weeks held steady or continued getting better through that full year.
What the Clinical Trials Measured
The major trial behind Dupixent’s FDA approval for EoE, called LIBERTY EoE TREET, tested patients over two phases. The first phase lasted 24 weeks. By that point, 85% of patients receiving weekly injections had achieved histological remission, meaning the immune cells causing damage in the esophagus had dropped to normal levels. Only 5% of patients on placebo reached that same threshold.
Patients who responded well at 24 weeks then continued into an extension phase for another 28 weeks, bringing the total treatment period to 52 weeks. Over that full year, improvements in tissue inflammation, swallowing symptoms, and the visible appearance of the esophagus on endoscopy were all maintained or continued to improve. Eosinophil counts dropped by roughly 96% from baseline in the weekly dosing group by week 52.
Why There’s No Set End Date
EoE is a chronic inflammatory condition. The immune system overreacts to certain triggers and sends inflammatory cells into the esophageal lining, causing swelling, narrowing, and difficulty swallowing. Dupixent works by blocking a specific part of this immune response, but it doesn’t cure the underlying tendency. That means stopping treatment would likely allow inflammation to return, similar to how stopping a daily asthma controller medication leads to worsening symptoms.
There isn’t yet published data showing exactly how quickly symptoms and inflammation come back after discontinuation. The clinical trials weren’t designed to answer that question directly. But because EoE behaves like other chronic immune-mediated conditions, most specialists treat Dupixent as a maintenance therapy you stay on as long as it’s working and tolerated.
The Injection Schedule
The FDA-approved dose for EoE is 300 mg injected under the skin once per week. This applies to adults and adolescents 12 years and older who weigh at least 40 kg (about 88 pounds). That weekly schedule is notably more frequent than the every-two-week dosing used for some of Dupixent’s other approved conditions like eczema or asthma.
The LIBERTY EoE TREET trial did test an every-two-week dosing schedule as well. At 52 weeks, 74% of patients on that less frequent schedule achieved histological remission, compared to 85% on weekly dosing. Both schedules worked, but weekly injections produced a higher response rate. Your prescriber may discuss whether a less frequent schedule could be appropriate for you at some point, though the standard recommendation remains weekly.
What to Expect in the First Months
Most patients in clinical trials began seeing measurable improvement within the first 24 weeks. That’s when the biggest changes in esophageal inflammation were documented. Swallowing difficulties typically improve over that same window, though some people notice changes sooner. The 24-to-52-week period is where gains solidify and, for some patients, continue to build. If you’ve been on Dupixent for six months and your endoscopy and symptoms show good improvement, the data suggests that staying on treatment will maintain those results.
Side Effects Over the Long Term
Through 52 weeks of treatment, the most commonly reported side effect was injection-site reactions, occurring in about 14% of patients on weekly dosing. These typically involve redness, swelling, or mild pain at the injection site. The trial did not flag any new safety concerns emerging between weeks 24 and 52, which is reassuring for longer-term use. That said, 52 weeks is still a relatively short window for a medication intended to be used indefinitely, and real-world experience over years will fill in the picture further.
Very few patients in the trials needed emergency esophageal dilation procedures while on treatment, with only about 1-3% requiring one. For a condition where food impactions and dilations can become a recurring problem, that’s a meaningful practical benefit.
The Bottom Line on Duration
Plan for Dupixent to be part of your routine for the foreseeable future. The current evidence supports ongoing weekly injections without a planned stop date. If your response is strong and sustained, your specialist may eventually explore spacing out doses, but that’s an individualized decision without firm guideline support yet. Stopping entirely carries the risk of inflammation returning, though the exact timeline for relapse after discontinuation isn’t well defined in published research.